Thymectomy for non-thymomatous myasthenia gravis

Area of Science:

• Neurology
• Immunology
• Surgical Oncology

Background:

• Myasthenia gravis (MG) is treated with steroids, immunosuppressants, plasma exchange, IV immunoglobulin, and thymectomy.
• Evidence supports some non-surgical therapies for MG, but clinical practice varies regarding thymectomy's role.
• Significant uncertainty exists about the efficacy of thymectomy in managing MG.

Purpose of the Study:

• To evaluate the efficacy and safety of thymectomy for non-thymomatous myasthenia gravis.
• To synthesize evidence from randomized controlled trials (RCTs) on thymectomy in MG management.

Main Methods:

• Searched multiple databases (Cochrane, CENTRAL, MEDLINE, EMBASE, LILACS) up to March 2013 for RCTs.
• Included randomized or quasi-randomized trials comparing thymectomy with no treatment or medical management.
• Two authors independently reviewed studies, extracted data, and assessed risk of bias.

Main Results:

• No randomized controlled trials (RCTs) were identified that tested thymectomy's efficacy in treating myasthenia gravis.
• Due to the absence of RCTs, no further analysis could be performed.

Conclusions:

• Currently, there is no RCT literature to support conclusions on thymectomy's efficacy for myasthenia gravis.
• Observational studies suggest potential benefits of thymectomy in MG.
• A randomized controlled trial is necessary to determine the usefulness and extent of thymectomy's benefit in MG.